By Counterforce Health Team in Natpara (parathyroid hormone) —

How to Get Natpara (Parathyroid Hormone) Covered by Aetna CVS Health in Ohio: 2025 Discontinuation Guide

Answer Box: Natpara Coverage with Aetna CVS Health in Ohio

Critical Update: Takeda permanently discontinued Natpara manufacturing in 2024. The U.S. Special Use Program ends December 31, 2025. For existing patients in Ohio with Aetna CVS Health coverage:

  1. Verify current coverage through your CVS Caremark member portal or call (866) 752-7021
  2. Submit prior authorization via your specialty pharmacy (CVS Specialty) with endocrinologist documentation
  3. Plan transition therapy with your provider before the December 2025 cutoff

New prescriptions are generally denied due to discontinued manufacturing. Focus on securing remaining doses and alternative treatments.

Table of Contents

  1. Current Natpara Availability Status
  2. Aetna CVS Health Coverage Requirements
  3. Prior Authorization Process
  4. Common Denial Reasons & Solutions
  5. Appeals Process in Ohio
  6. Financial Assistance Options
  7. Alternative Treatment Planning
  8. FAQ

Current Natpara Availability Status

Natpara (parathyroid hormone) faces a critical supply situation that affects all insurance coverage decisions, including Aetna CVS Health plans in Ohio.

Manufacturing Discontinuation Timeline

  • 2024: Takeda permanently ceased global manufacturing
  • Through December 31, 2025: Limited supply available via Special Use Program for existing patients only
  • After January 1, 2026: No commercial supply available

This timeline means that new patient starts are typically denied by all insurers, including Aetna CVS Health, regardless of medical necessity documentation.

Note: Even with perfect prior authorization documentation, coverage may be denied due to manufacturer supply constraints rather than medical criteria.

Aetna CVS Health Coverage Requirements

For patients currently enrolled in the Natpara Special Use Program, Aetna CVS Health maintains specific coverage criteria:

Formulary Status

  • Specialty Tier: Non-Preferred Specialty (NPSP) when covered
  • Distribution: CVS Specialty Pharmacy only
  • Prior Authorization: Required for all requests
  • Quantity Limits: Typically 30-day supply maximum

Medical Necessity Criteria

Requirement Documentation Needed Source
Diagnosis confirmation ICD-10 codes for hypoparathyroidism Clinical notes
Failed standard therapy Calcium/vitamin D inadequacy documented Lab values, dosing history
Specialist prescriber Endocrinologist or nephrologist DEA number verification
REMS enrollment Patient registered in safety program Takeda confirmation
Monitoring plan Serum calcium tracking protocol Provider attestation

Source: Aetna specialty medication precertification requirements

Prior Authorization Process

Step-by-Step Submission

1. Provider Initiates Request

  • Submit via CVS Specialty Pharmacy coordination
  • Use Aetna specialty medication precertification form
  • Timeline: 3-5 business days for standard review

2. Required Clinical Documentation

  • Previous therapy history with calcium/vitamin D
  • Laboratory evidence of hypocalcemia despite standard treatment
  • Confirmation of hypoparathyroidism diagnosis
  • Current serum calcium, phosphorus, and 25-hydroxyvitamin D levels

3. REMS Program Verification

  • Patient must be enrolled in Natpara REMS Program
  • Prescriber must be certified through Takeda
  • Pharmacy must be authorized for distribution

Clinician Corner: Medical Necessity Letter

When submitting prior authorization for Natpara with Aetna CVS Health, your medical necessity letter should include:

  • Diagnosis specifics: Primary hypoparathyroidism or post-surgical hypoparathyroidism with ICD-10 codes
  • Treatment failures: Document inadequate control with optimized calcium carbonate/citrate and calcitriol/paricalcitol dosing
  • Clinical rationale: Persistent symptomatic hypocalcemia, quality of life impacts, or complications from high-dose supplementation
  • Safety considerations: Acknowledgment of osteosarcoma risk and appropriate patient counseling
  • Monitoring plan: Regular serum calcium monitoring per FDA labeling requirements

Reference: FDA Natpara prescribing information for complete safety and efficacy data

Common Denial Reasons & Solutions

Denial Reason Solution Strategy Required Documentation
"No longer manufactured" Confirm Special Use Program enrollment Takeda program verification letter
"Not medically necessary" Document standard therapy failure Lab values, dosing records, symptoms
"Experimental/investigational" Cite FDA approval status FDA labeling, ICD-10 alignment
"Step therapy not completed" Request step therapy exception Prior failure documentation
"Non-formulary" Submit formulary exception Medical necessity letter, alternatives tried

Source: Based on typical specialty drug denial patterns and payer policies

Appeals Process in Ohio

Ohio residents with Aetna CVS Health have specific appeal rights and timelines:

Internal Appeals (First Level)

  • Timeline: File within 180 days of denial
  • Aetna review period: 30 days standard, 72 hours expedited
  • Submission: Call (866) 752-7021 or submit via member portal

External Review (Ohio Department of Insurance)

  • Eligibility: After exhausting internal appeals
  • Timeline: 180 days from final internal denial to request external review
  • Process: File with Aetna, who forwards to Ohio DOI
  • Decision: Binding on insurer if overturned
Ohio Advantage: Even if Aetna claims your case isn't eligible for external review, the Ohio Department of Insurance can independently determine eligibility and order a review.

Contact Information for Ohio Appeals

  • Ohio Department of Insurance Consumer Services: 1-800-686-1526
  • Aetna Member Services: Number on your insurance card
  • CVS Caremark Prior Authorization: (866) 785-5714

Source: Ohio Department of Insurance external review process

Financial Assistance Options

Manufacturer Support (Limited Time)

  • Takeda Patient Support: Available through December 2025
  • Eligibility: Commercial insurance required (not Medicare/Medicaid)
  • Benefit: Copay reduction to as low as $5 per dose
  • Contact: 1-844-829-2736

Foundation Assistance

  • Hypoparathyroidism Association (HPA): Provides grants for medication costs
  • Application: hypopara.org/patient-assistance
  • Coverage: Prescription costs, medical supplies, travel to specialists

Ohio-Specific Resources

  • Ohio Medicaid: Coverage available with prior authorization
  • Medicare Part D Extra Help: Reduces costs for eligible low-income beneficiaries
  • Hospital charity care: Many Ohio hospitals offer financial assistance programs

At Counterforce Health, we help patients navigate complex prior authorization requirements and turn insurance denials into targeted appeals. Our platform analyzes denial letters and plan policies to craft evidence-backed rebuttals that align with payer-specific criteria, helping patients get the medications they need.

Alternative Treatment Planning

Given the 2025 discontinuation, patients and providers should plan transition strategies:

Standard Management Options

  • Optimized calcium supplementation: Higher doses with multiple daily dosing
  • Active vitamin D analogs: Calcitriol, paricalcitol with careful monitoring
  • Thiazide diuretics: To reduce urinary calcium loss
  • Magnesium supplementation: Address concurrent hypomagnesemia

Emerging Alternatives

  • Teriparatide: Off-label use being studied in some centers
  • Clinical trials: Investigational PTH analogs in development
From our advocates: "We've seen patients successfully transition off Natpara by working closely with their endocrinologist to optimize calcium and vitamin D dosing schedules. The key is frequent monitoring during the transition period and having a clear plan for symptom management."

FAQ

Q: Can I get Natpara covered by Aetna CVS Health as a new patient in Ohio? A: New prescriptions are generally denied due to manufacturing discontinuation. Only existing Special Use Program patients typically receive coverage.

Q: How long does Aetna CVS Health prior authorization take for Natpara? A: Standard review is 3-5 business days; expedited review (if medically urgent) is typically 72 hours.

Q: What if my Aetna plan lists Natpara as non-formulary? A: You can request a formulary exception with medical necessity documentation, though success rates are low due to supply constraints.

Q: Can I appeal to Ohio regulators if Aetna denies coverage? A: Yes, Ohio offers external review through independent medical experts after internal appeals are exhausted.

Q: Does step therapy apply to Natpara with Aetna CVS Health? A: Step therapy typically requires trying calcium/vitamin D optimization first, but exceptions can be requested with documentation of prior failures.

Q: Will my copay assistance continue through 2025? A: Takeda's copay program runs through the Special Use Program end date of December 31, 2025.

Q: What happens to my coverage after December 2025? A: No commercial supply will be available. Work with your endocrinologist to establish alternative treatment protocols.

Q: Can CVS Specialty help with prior authorization submission? A: Yes, CVS Specialty coordinates with prescribers to submit required documentation and follow up on authorization status.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions vary by individual plan and medical circumstances. Always consult with your healthcare provider and insurance company for specific coverage questions. For additional help with insurance appeals in Ohio, contact the Ohio Department of Insurance Consumer Services at 1-800-686-1526.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.